GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
Profit after tax (before exceptional items) up 23% to Rs 215 crores
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
This expansion follows the groundbreaking of a large-scale commercial drug product facility in Stein (CH), in another milestone for Lonza’s Drug Product Services (DPS) offering
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
This registration enables companies to register the products (Orodispersible films and Transdermal systems) in UAE for commercialization
Subscribe To Our Newsletter & Stay Updated
